Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Bladder Cancer Clinical Trial

— ALBAN  

Official title:

An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03799835
• Other study ID #: UC-0160/1717
• Secondary ID: 2017-004512-19
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: January 17, 2019
• Est. completion date: February 1, 2028

Study information

• Verified date: December 2023
• Source: UNICANCER
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, randomized, multicentric study in patients with high-risk non-muscle invasive bladder cancer who had never received BCG for this disease.

The objective is to evaluate the efficacy of atezolizumab as measured by recurrence-free survival.

Description:

ALBAN study will randomize 516 patients in 45 centers in Europe (France, Belgium and Spain), according to a ratio 1:1 in the following arms of treatment:

• Arm A (control arm): BCG only

• Arm B (experimental arm): BCG+ atezolizumab

The are two factors of stratifications (center and CIS).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 516
• Est. completion date: February 1, 2028
• Est. primary completion date: April 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent form after the last endoscopic surgery (TURBT)

2. Adult man and women ( age =18 years)

3. Any high risk non muscle invasive urothelial carcinoma histologically confirmed (mixed histology tumors allowed if urothelial carcinoma histology is predominant) defined on the TURBT as any of the following :

• T1 tumor and/or

• High grade (WHO 2004) and/or

• Grade 3 (WHO1973) and/or

• Carcinoma in situ (CIS)

4. Tumor tissue available from the surgery for central confirmation of the diagnosis and analysis the expression of PD-L1

5. At least one additional (second) resection of the primary tumor has been performed in any of the following cases [without upstaging towards Muscle Invasive Bladder Cancer (EAU guidelines, 2017)] :

• T1 tumors at physician's discretion,

• incomplete initial TURB,

• no muscle in the specimen (can be omitted if TaLG/G1 tumors or primary CIS only was found)

6. Absence of metastasis in pelvis, abdomen, or chest, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging (MRI) scan no more than 90 days prior to the first study treatment

7. Eastern Cooperative Oncology Group (ECOG) performance status of =2

8. Life expectancy =12 weeks

9. Systolic blood pressure (BP) <160 mmHg and diastolic BP <95 mmHg, as documented within 7 days prior to the first study treatment (hypertension allowed provided it is controlled)

10. Adequate hematologic and end-organ function, as defined by the following laboratory results obtained within 7 days prior to the first study treatment:

• absolute neutrophil count (ANC) =1500 cells/µL

• white blood cell (WBC) counts >2500/µL

• Lymphocyte count =300/µL

• Platelet count =100,000/µL

• Hemoglobin =9.0 g/dL

• aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), and alkaline phosphatase =2.5 × the upper limit of normal (ULN)

• Serum bilirubin =1.0 × ULN Patients with known Gilbert disease who have serum bilirubin level =3 × ULN may be enrolled.

• Partial thromboplastin time (PTT)/Prothrombin Time (PT) =1.5 × ULN or international normalized ratio (INR) <1.7 × ULN

• Calculated creatinine clearance =20 mL/min (Cockcroft-Gault formula)

11. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab

12. Patients affiliated to the social security system

13. Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.

Exclusion Criteria:

1. Patient having received previous BCG therapy for bladder cancer

2. Any approved anti-cancer therapy, including systemic chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment. Hormone-replacement therapy or oral contraceptives are allowed

3. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or five half-lives of the drug, whichever is longer, prior to day 1 of study treatment

4. Malignancies other than urothelial cancer within 5 years prior to Day 1 of cycle 1 of treatment except the following:

• Patients with localized low risk prostate cancer (defined as Stage =T2b, Gleason score =7, and PSA at prostate cancer diagnosis =20 ng/mL [if measured]) treated with curative intent (radiotherapy and/or prostatectomy) and without prostate-specific antigen (PSA) recurrence are eligible.

• Patients with low risk prostate cancer (defined as Stage T1/T2a, Gleason score =7 and PSA =10 ng/mL) who are treatment-naive and undergoing active surveillance are eligible.

• Patients with malignancies of a negligible risk of metastasis or death (e.g., risk of metastasis or death <5% at 5 years) are eligible provided they meet all of the following criteria: malignancy treated with expected curative intent (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) and no evidence of recurrence or metastasis by follow-up imaging and any disease-specific tumor markers.

5. Pregnancy or breastfeeding

6. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

7. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation

8. History of autoimmune disease or history of immunosuppression, or conditions associated with congenital or acquired immune deficiency , including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis (see Appendix 6 for a more comprehensive list of autoimmune diseases)

• Patients with a history of autoimmune-related hypothyroidism/hyperthyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.

• Patients with controlled Type I diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.

• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan may be eligible.

• History of radiation pneumonitis in the radiation field (fibrosis) is permitted.

9. Serum albumin <2.5 g/dL

10. Known HIV infection

11. Patients with active hepatitis B virus (HBV; chronic or acute; defined as having a positive hepatitis B surface antigen (HBsAg) test prior the randomisation) or hepatitis C.

• Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody (HBc Ab) and absence of HBsAg) are eligible. HBV DNA must be obtained in these patients prior to randomisation.

• Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

12. Known active tuberculosis

13. Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia

14. Signs or symptoms of urinary infection and/or other signs and symptoms > grade 1 (NCI CTCAE v5.0) within 2 weeks prior to Cycle 1, Day 1

• Patients receiving therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1, Day 1 are not eligible

• Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or to prevent chronic obstructive pulmonary disease exacerbation) are eligible.

15. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months before Cycle1, Day 1, unstable arrhythmias, or unstable angina.

• Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction <50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.

16. Major surgical procedure other than for diagnosis within 4 weeks prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study

17. Prior allogeneic stem cell or solid organ transplant

18. Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation if such a live, attenuated vaccine will be required during the study

• Influenza vaccination should be given during influenza season only (approximately October through May in the Northern Hemisphere and approximately April through September in the Southern Hemisphere). Patients must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to Cycle 1, Day 1, at randomization, during treatment or within 5 months following the last dose of atezolizumab (for patients randomized to atezolizumab).

19. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications

20. Prior treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies

21. Treatment with systemic immunostimulatory agents (including but not limited to interferons, interleukin 2 (IL-2)) within 6 weeks or five half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1

22. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (anti-TNF) agents) within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic immunosuppressive medications during the trial

• Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea, multiple doses for contrast allergy) may be enrolled in the study.

• The use of inhaled or low-dose (e.g., =10 mg/day prednisone) corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, mineralocorticoids (e.g., fludrocortisone for adrenal insufficiency) and low-dose corticosteroids for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.

23. Person deprived of their liberty or under protective custody or guardianship

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• BCG
Intravesical administration OncoTice wil be used only under two conditions : BCG Medac® unavailable and the patient has received at minimum one instillation of BCG Medac®
• Atezolizumab
IV perfusion

Locations

Country	Name	City	State
Belgium	Groupe Jolimont - Hôpital de Jolimont	Haine Saint Paul
Belgium	AZ Delta - Campus Rumbeke	Roeselare
France	Centre Hospitalier Universitaire Angers	Angers
France	Centre Hospitalier Universitaire Bordeaux	Bordeaux
France	Hôpital G. Montpied	Clermont-Ferrand
France	Clinique Claude Bernard	Ermont
France	CHU Grenoble	Grenoble
France	Hôpital privé Toulon - Sainte Marguerite	Hyères
France	Hôpital du Kremlin-Bicêtre	Le Kremlin-Bicêtre
France	Hôpital privé de la Louvière	Lille
France	Hôpital Saint Vincent	Lille
France	Hôpital Saint Philibert	Lomme
France	Centre Hospitalier Universitaire Marseille	Marseille
France	Insitut Paoli Calmette	Marseille
France	Centre Hospitalier Universitaire Nîmes	Nîmes
France	Centre Hospitalier Universitaire Tenon	Paris
France	Groupe Hospitalier Paris Saint Joseph	Paris
France	Hôpital Cochin	Paris
France	Hôpital Diaconesses- Croix Saint Simon	Paris
France	Hôpital européen Georges Pompidou	Paris
France	Hôpital La Pitié Salpétrière	Paris
France	Hôpital Saint Louis	Paris
France	Institut Mutualiste Montsouris	Paris
France	Centre Hospitalier Universitaire Lyon Sud	Pierre-Bénite
France	Centre CARIO-HPCA	Plérin
France	Centre Hospitalier Universitaire Rennes	Rennes
France	Hôpitaux d'instruction des armées Begin	Saint-Mandé
France	Hôpital Foch	Suresnes
France	Hôpitaux Leman	Thonon-les-Bains
France	Institut Claudius Regaud	Toulouse
France	Centre Hospitalier Universitaire Tours	Tours
France	Institut Gustave Roussy	Villejuif
Spain	Hospital Universitario A Coruña	A Coruña
Spain	Hospital Universitario de Jerez de la Frontera	Cadiz
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Ramon y Cajal	Madrid
Spain	Hospital General Universitario Morales Meseguer	Murcia
Spain	Hospital Universitario de Canarias	Santa Cruz De Tenerife

Sponsors (2)

Lead Sponsor	Collaborator
UNICANCER	Hoffmann-La Roche

Countries where clinical trial is conducted

Belgium,  France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence-free survival	Recurrence is defined as reappearance of disease (local recurrence or occurrence of any metastasis) after the start of therapy.	2 years
Secondary	Progression-free survival	Progression- free survival defined as the time from randomization to the date of disease progression defined as increase of stage from Ta to T1 or from CIS to T1; progression to Muscle Invasive Bladder Cancer (T= 2) or to lymph node N+ or to distant disease M+; the date of progression being determined by the endoscopic resection (TURBT) for a local relapse or by CT scan in case of non-local relapse.	From randomization to the date of progression, assessed up to 5 years
Secondary	Disease-specific survival	Disease-specific survival defined as the time from randomization to the date of death from bladder cancer.	From randomization to the date of death, assessed up to 5 years
Secondary	Overall Survival	Overall Survival defined as the time from randomization to the date of death from any cause.	From randomization to the date of death, assessed up to 5 years
Secondary	Disease worsening in each arm	Disease worsening, defined as cystectomy or change in therapy indicative, including systemic chemotherapy or radiation therapy. The date of diagnosis (cystoscopy or CT scan) leading to cystectomy or chemotherapy will be considered as the time of disease worsening.	From randomization to the date of death, assessed up to 5 years
Secondary	Complete response in each arm	Complete response is assessed by cystoscopy and cytology.	6 weeks and 2 years after randomization
Secondary	Complete response among patients with CIS	Complete response is assessed by cystoscopy and cytology.	6 weeks and 2 years after randomization
Secondary	National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	The frequency, nature, and severity of adverse events graded according to NCI CTCAE v5.0 and according to the immune-related adverse event (irAE).	Throughout study completion, assessed up to 5 years
Secondary	Quality of life questionnaire (QLQ): QLQ-C30 questionnaire (EORTC)	This self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.; The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.; All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.	At randomization, every 12 weeks for years 1 and 2 after randomization, then every 24 weeks for years 3 to 5 after randomization